Jazz Pharmaceuticals Q3 Swings to Adjusted Loss, Revenue Rises

04:29 PM EST, 11/02/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) reported a Q3 adjusted loss late Monday of $3.88 per diluted share, compared with earnings of $8.13 a year earlier. Analysts polled by FactSet expected a loss of $3.86. Revenue in the three months ended Sept. 30 rose to $1.24 billion from $1.13 billion a year earlier. Analysts projected $1.21 billion. The company raised its full-year revenue guidance to $4.775 billion to $4.85 billion from its previous forecast of $4.6 billion to $4.75 billion. Analysts projected $4.73 billion.